US FDA Classifies Eugia Unit-III Inspection as OAI; Aurobindo Pharma Says No Financial or Operational Impact 12/06/2026 / Regulatory Filings / Regulatory Inspection Outcome US FDA Classifies Eugia Unit-III Inspection as OAI; Aurobindo Pharma Says No Financial or Operational Impact Read Post »
Concord Biotech Successfully Completes ANVISA Inspection at Limbasi API Manufacturing Facility 12/06/2026 / Regulatory Filings / Regulatory Inspection Outcome Concord Biotech Successfully Completes ANVISA Inspection at Limbasi API Manufacturing Facility Read Post »
Ajanta Pharma receives US FDA Form 483 with 5 observations for Paithan facility 22/04/2026 / Material Events / Regulatory Inspection Outcome Ajanta Pharma receives US FDA Form 483 with 5 observations for Paithan facility Read Post »
